1Negoro S,Masuda N,Takada Y,et al.Randomised phase Ⅲ trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer[J].Br J Cancer,2003,88(3):335-341.
2Fish MD.Irinotecan/cisplatin versus vindesine/cisplatin versus irinotecan alone in advanced non-small-cell lung cancer[J].Clin Lung Cancer,2001,2(3):180-181.
3Fukuda M,Oka M,Soda H,et al.Phase Ⅱ study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer[J].Cancer Chemother Pharmacol,2004,54(6):573-577.
4Oshita F,Yamada K,Saito H,et al.Phase Ⅱ study of nedaplatin and irinotecan for elderly patients with advanced non-small-cell lung cancer[J].J Exp Ther Oncol,2004,4(4):343-348.
5Yamamoto N,Fukuoka M,Negoro SI,et al.Randomised phase Ⅱ study of docetaxel /cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer:a West Japan Thoracic Oncology Group Study (WJTOG9803)[J].Br J Cancer,2004,90(1):87-92.
6Pectasides D,Pectasides M,Farmakis D,et al.Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small cell lung cancer:a randomized phase Ⅱ trial[J].Ann Oncol,2005,16(2):294-299.
7Socinski MA,Sandler AB,Miller LL,et al.Irinotecan (CPT-11) in triplet combinations in patients with advanced non-small-cell lung cancer:a review and report of a phase Ⅰ/Ⅱ trial[J].Clin Lung Cancer,2001,2(Suppl 2):26-33.
8Pectasides D,Visvikis A,Kouloubinis A,et al.Weekly chemotherapy with carboplatin,docetaxel and irinotecan in advanced non-small-cell lung cancer:a phase Ⅱ study[J].Eur J Cancer,2002,38(9):1194-1200.
9Fujita A,Ohkubo T,Hoshino H,et al.Phase Ⅱ study of cisplatin,ifosfamide,and irinotecan with rhG-CSF support in patients with stage Ⅲ b and Ⅳ non-small-cell lung cancer[J].Br J Cancer,2003,89(6):1008-1012.
10Kudoh S,Fujiwara Y,Takano K,et al.Phase Ⅱ study of Irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer[J].J Clin Oncol,1998,16(3):1068-1074.
3Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database [J]. J Clin Oncol,2006,24(28) :,1539-4544.
4Noda K,Nishiwaki Y,Kawahara M,et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer [J]. N Engl J Med, 2002,346 (2) : 85- 91.
5Hanna NH,Einhorn L,Sandler A,et al. Randomized, phase Ⅲ trial comparing irinotecan/cisplatin(IP) with etoposide/cisplatin (EP) in patients with previously untreated,extensive-stage (ES) small cell lung cancer (SCLC) [J]. J Clin Oncol,2005,16(5):622.
6Akinobu K, Kado S, Kaneda N, et al. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats [J]. Cancer Chemother Pharmacol, 2000, 46 (3):211-220.
7Chiu CJ, McArdle AH, Brown R, et al. Intestinal mucosal lesion in low flow states [J]. Arch Surg, 1970,101 (4): 478- 485.
8Kurita A, Kado S, Kaneda N, et al. Modified irinoteean hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats [J]. Cancer Chemother Pharmacol, 2000,46 (3) : 211 - 220.
9Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma [ J]. Dig Dis Sci, 2005, 50: 2218.
10Bonnetain F, Bouche O, Conroy T, et al. Longitudinal quality of life study in patients with metastatic gastric cancer: Analysis modalities and clinical applicability of QoL in randomized phase Ⅱ trial in a digestive oncology [ J]. Gastroenterol Clin Biol, 2005, 29: 1113.
